We were the first group to demonstrate that the increased expression of METCAM in a human prostate cancer cell line, LNCaP, enhances its EMT (epithelial-to-mesenchymal transition) activity, as shown in analyses of augmented motility and invasiveness. Here, MCAM is linked to prostate cancer.